Antibody-drug conjugate · Cytotoxic, directed at Nectin-4 · developed by Astellas
Enfortumab vedotin is an antibody-drug conjugate in which a human IgG1 kappa antibody binds Nectin-4, an adhesion protein on the cell surface. After the complex is internalized, the microtubule-disrupting agent MMAE is released through protease-cleavage of its linker, leading to cell cycle arrest and apoptosis. It is used in the treatment of muscle-invasive bladder cancer.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 4, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07475806 | Phase 2 | Muscle-invasive Bladder Cancer | Recruiting | PFE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Muscle-invasive Bladder Cancer
Updated Nov 15, 2026.